# PTH and vitamin D in CKD

Andrew Bland, MD, FACP, FAAP · October 27, 2026

Nondialysis CKD: distinguish nutritional vitamin D repletion, activated vitamin D for PTH suppression, the clinical-outcome evidence gap and Dr Bland’s individualized practice threshold.

## Why PTH rises

Reduced renal vitamin D activation, phosphate burden and altered calcium balance can stimulate secondary hyperparathyroidism as CKD progresses. PTH can rise while serum phosphate remains within the reference range. Interpret calcium, phosphate, alkaline phosphatase, 25-OH vitamin D and PTH together and as serial trends.

## Two forms, two purposes

Ergocalciferol (D2) and cholecalciferol (D3) replenish nutritional vitamin D stores, assessed with 25-OH vitamin D. Their conversion to the active hormone includes renal 1α-hydroxylation. Calcitriol (Rocaltrol), activated 1,25-(OH)2 vitamin D3, bypasses that step and suppresses PTH. Calcitriol does not replace correction of low 25-OH vitamin D stores.

## What is established, and what remains uncertain

Activated vitamin D lowers PTH. Evidence that treating secondary hyperparathyroidism this way improves fractures, cardiovascular events or survival in nondialysis CKD remains insufficient. PRIMO and OPERA tested paricalcitol, not calcitriol: PTH suppression did not improve their primary cardiac structural endpoints, and hypercalcemia was more frequent. Those results do not establish that selected patients with severe progressive disease can never benefit.

## Guideline frame

KDIGO does not define an optimal PTH target for adults with nondialysis CKD. Evaluate reversible contributors when PTH is persistently elevated or rising. Calcitriol and vitamin D analogs are not recommended routinely in G3a–G5; selective use may be reasonable in G4–G5 with severe progressive secondary hyperparathyroidism. The guideline does not specify 300 pg/mL as a treatment cutoff.

## Dr Bland’s practice

Dr Bland uses persistently elevated or rising PTH above about 300 pg/mL as a point to consider calcitriol (Rocaltrol), after evaluating reversible contributors. For PTH suppression he prefers activated vitamin D rather than relying on nutritional D2/D3 alone. This is an individualized faculty practice threshold, not a proven clinical-outcome threshold or a KDIGO target. Deficiency in 25-OH vitamin D still requires attention.

## Return to Case 4 and monitor

Carol’s G3b CKD, PTH 260→400, normal calcium/phosphate and 25-OH vitamin D of 17 call for correcting deficiency and reviewing the trend and other contributors first. A single PTH of 400 does not make calcitriol automatic. If selected, monitor calcium, phosphate and PTH; excessive suppression can promote low bone turnover. High calcium or phosphate should prompt reassessment.

## Sources

- [KDIGO 2017 CKD-MBD update: recommendations 3.1.3, 4.2.1 and 4.2.2](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2017-CKD-MBD-GL-Update-Synopsis.pdf)
- [PRIMO randomized trial](https://pubmed.ncbi.nlm.nih.gov/22337679/)
- [OPERA randomized trial](https://pubmed.ncbi.nlm.nih.gov/24052631/)
- [Calcitriol versus paricalcitol trial in CKD stages 3–4](https://pubmed.ncbi.nlm.nih.gov/24970869/)